Actelion is initiating Phase III clinical development of cadazolid in patients suffering from Clostridium difficile associated diarrhea
Actelion announced that it will initiate a Phase III clinical development program to assess the efficacy and safety of cadazolid in patients with Clostridium difficile-associated diarrhea (CDAD).
The Phase III program consists of two identical multi-center, randomized, double-blind studies comparing the efficacy and safety of cadazolid, (250 mg administered orally twice daily for 10 days) versus vancomycin, (125 mg administered orally four times daily for 10 days) in subjects with Clostridium difficile-associated diarrhea (CDAD).
The program is designed to determine whether the clinical response after administration of cadazolid is non-inferior to vancomycin in patients with CDAD, and whether administration of cadazolid is superior to vancomycin in the sustained clinical response.
The program is expected to enroll more than 1'250 patients worldwide, and is planned to commence enrollment in the fourth quarter of 2013.
Jean-Paul Clozel, M.D. and Chief Executive Officer of Actelion commented: "The cadazolid Phase III program will address the essential clinical and commercial requirements for a novel CDAD therapy to be successful, with a focus on making a meaningful difference for patients. Evidence of a superior sustained cure compared to vancomycin, including in hypervirulent strains, would go a long way to meeting the most pressing current medical need. The promising profile of cadazolid underlines Actelion's commitment to finding new classes of antibiotics which have a reduced risk of developing resistance."
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Charley_Dewberry
Fighting germs with replicas of natural compounds
George_Emil_Palade
Category:EC_3.4.22
Immunity_(medical)
Gut-associated_lymphoid_tissue

Non-natural biomedical polymers produced from microorganisms
Category:Anabolic_steroids
